Cellectar Biosciences CLRB 深 滬
已收盤 05-08 16:00:00 美东时间
3.10
-0.200
-6.06%
華盛通- 最 高3.23
- 今 開3.21
- 成交量 68.72万股
- 最 低 2.88
- 昨 收 3.30
- 總市值 1314.44万
- 52周最高 20.595
- 市盈率 靜 --
- 換手率 16.21%
- 52周最低 2.43
- 委 比 31.90%
- 總股本 424.01万
- 歷史最高 276000.00
- 量 比 0.06
- 振 幅 10.61%
- 歷史最低 2.43
- 每 手 1
- 風險率 2.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What's Going With Cellectar Biosciences Stock On Wednesday?
Cellectar shares slip premarket after rally as CLOVER WaM data, financing plans, and technical signals shape outlook for CLRB stock.
05-06 21:17
Crude Oil Down 4%; PayPal Shares Fall After Q1 Results
US stocks rise, Nasdaq gains 1%. Dow up 0.57%, Nasdaq up 1.03%, S&P 500 up 0.84%. Materials up 2.1%, financials down 0.2%. PayPal shares fall 9%.
05-06 01:13
Dow Jumps Over 300 Points; Tyson Foods Posts Upbeat Earnings
US stocks rise, Dow gains 300 points. Materials jump 1.8%, real estate falls 0.2%. Pfizer's Q1 earnings beat expectations. Asian markets close lower.
05-05 23:45
Dow Jumps Over 300 Points; Pfizer Posts Upbeat Earnings
US stocks rise, Dow gains 300 points. Materials jump 1.8%, real estate falls 0.2%. Pfizer's Q1 earnings beat expectations. Asian markets close lower.
05-05 23:44
Cellectar Biosciences announces up to $140M financing deal; shares surge
Cellectar Biosciences (CLRB) entered agreements with institutional investors and management to raise capital. The deal includes ~$35M upfront funding plus up to ~$105M tied to milestone-based securiti...
05-05 21:02
Market-Moving news for May 5th
PINS: 19% | Pinterest shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance above estimates. CLRB: 145% | Cellectar Biosciences Phase
05-05 19:19
Cellectar Biosciences Phase 2b CLOVER WaM 12-Month Data Shows 83.6% ORR And Durable Responses Exceeding 18 Months In Post-BTKi Patients
83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response of 17.8 monthsFDA-requested dataset with ≥12-month follow-up on all patients strengthens regulatory positioning for
05-05 19:11
Cellectar Biosciences Announces The Acceptance Of An Abstract For Poster Presentation At The American Society Of Clinical Oncology Annual Meeting Taking Place May 29 - June 2 In Chicago, Illinois
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for
04-21 22:05
Cellectar Biosciences Enrolls First Participant In Its Phase 1b Study Of CLR 121125 To Treat Triple Negative Breast Cancer
Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the first patient has been
04-14 20:45
